OBJECTIVES: To determine the association between the epsilon2 and epsilon4 alleles of apolipoprotein E (ApoE) and independent measures of cognitive decline and non-cognitive symptomatology in late onset Alzheimer's disease. METHODS: The frequency of the epsilon2 and epsilon4 alleles of ApoE and their association with measures of cognitive decline and non-cognitive symptomatology were assessed in a population based case register study of 164 patients with late onset Alzheimer's disease from the east Lambeth and south Southwark districts of south London. RESULTS: Analysis of a wide range of non-cognitive symptoms against ApoE epsilon4 genotype showed no significant association but a positive relation was found between ApoE epsilon2 genotype and depressive symptomatology (P = 0.004). No relation was found between measurements of cognitive decline and the presence of the ApoE epsilon4 allele. A trend for decreasing age at onset of 3 to 4 years in carriers of the ApoE epsilon4 allele was found, confirming earlier studies. CONCLUSION: Presence of the epsilon4 allele of ApoE is associated with an earlier age at onset but does not seem to be related to either a more severe psychopathology or a more rapid progression of the illness. The epsilon2 allele of ApoE is associated with depressive symptomatology in late onset Alzheimer's disease.
OBJECTIVES: To determine the association between the epsilon2 and epsilon4 alleles of apolipoprotein E (ApoE) and independent measures of cognitive decline and non-cognitive symptomatology in late onset Alzheimer's disease. METHODS: The frequency of the epsilon2 and epsilon4 alleles of ApoE and their association with measures of cognitive decline and non-cognitive symptomatology were assessed in a population based case register study of 164 patients with late onset Alzheimer's disease from the east Lambeth and south Southwark districts of south London. RESULTS: Analysis of a wide range of non-cognitive symptoms against ApoE epsilon4 genotype showed no significant association but a positive relation was found between ApoE epsilon2 genotype and depressive symptomatology (P = 0.004). No relation was found between measurements of cognitive decline and the presence of the ApoE epsilon4 allele. A trend for decreasing age at onset of 3 to 4 years in carriers of the ApoE epsilon4 allele was found, confirming earlier studies. CONCLUSION: Presence of the epsilon4 allele of ApoE is associated with an earlier age at onset but does not seem to be related to either a more severe psychopathology or a more rapid progression of the illness. The epsilon2 allele of ApoE is associated with depressive symptomatology in late onset Alzheimer's disease.
Authors: G B Frisoni; S Govoni; C Geroldi; A Bianchetti; L Calabresi; G Franceschini; M Trabucchi Journal: Ann Neurol Date: 1995-05 Impact factor: 10.422
Authors: A S Henderson; S Easteal; A F Jorm; A J Mackinnon; A E Korten; H Christensen; L Croft; P A Jacomb Journal: Lancet Date: 1995-11-25 Impact factor: 79.321
Authors: J Kuusisto; K Koivisto; K Kervinen; L Mykkänen; E L Helkala; M Vanhanen; T Hänninen; K Pyörälä; Y A Kesäniemi; P Riekkinen Journal: BMJ Date: 1994-09-10
Authors: A L Pritchard; J Harris; C W Pritchard; J Coates; S Haque; R Holder; P Bentham; C L Lendon Journal: J Neurol Neurosurg Psychiatry Date: 2006-09-15 Impact factor: 10.154
Authors: N Scarmeas; J Brandt; M Albert; D P Devanand; K Marder; K Bell; A Ciappa; B Tycko; Y Stern Journal: Neurology Date: 2002-04-23 Impact factor: 9.910
Authors: S Cosentino; N Scarmeas; E Helzner; M M Glymour; J Brandt; M Albert; D Blacker; Y Stern Journal: Neurology Date: 2008-04-09 Impact factor: 9.910